{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T15:54:41Z","timestamp":1774713281896,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.urolonc.2021.11.015","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T07:42:04Z","timestamp":1639986124000},"page":"195.e13-195.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8267-1948","authenticated-orcid":false,"given":"Sean A.","family":"Fletcher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otis W.","family":"Brawley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Kates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2021.11.015_bib0001","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1475-6773.2012.01386.x","article-title":"A systematic review of community-based participatory research to enhance clinical trials in racial and ethnic minority groups","volume":"47","author":"De Las Nueces","year":"2012","journal-title":"Health Serv Res"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0002","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1245\/s10434-007-9500-y","article-title":"Participation in surgical oncology clinical trials: gender-, race\/ethnicity-, and age-based disparities","volume":"14","author":"Stewart","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0003","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1371\/journal.pctr.0010009","article-title":"Factors that can affect the external validity of randomised controlled trials","volume":"1","author":"Rothwell","year":"2006","journal-title":"PLoS Clin Trials"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0004","unstructured":"Section 131. Requirement of Inclusion in Research. NIH Revitalization Act of 1993. https:\/\/orwh.od.nih.gov\/sites\/orwh\/files\/docs\/NIH-Revitalization-Act-1993.pdf. Accessed March 17, 2021"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0005","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1200\/JCO.2004.03.160","article-title":"Enrollment of African Americans onto clinical treatment trials: study design barriers","volume":"22","author":"Adams-Campbell","year":"2004","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0006","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cct.2014.08.004","article-title":"Strategies addressing barriers to clinical trial enrollment of underrepresented populations: a systematic review","volume":"39","author":"Heller","year":"2014","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0007","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/j.juro.2016.10.101","article-title":"Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors","volume":"197","author":"Morales","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0008","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.eururo.2020.02.012","article-title":"Systematic review of the therapeutic efficacy of bladder-preserving treatments for Non\u2013muscle-invasive bladder cancer following intravesical bacillus calmette-gu\u00e9rin","volume":"78","author":"Li","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0009","unstructured":"U.S. Food and Drug Administration. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment. Published online February 2018:13."},{"key":"10.1016\/j.urolonc.2021.11.015_bib0010","unstructured":"U.S. Cancer Statistics Working Group. U.S. cancer statistics data visualizations tool, based on 2019 submission data (1999-2017): U.S. department of health and human services, centers for disease control and prevention and national cancer institute. www.cdc.gov\/cancer\/dataviz, released in June 2020. Accessed on March 29th, 2021."},{"key":"10.1016\/j.urolonc.2021.11.015_bib0011","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/JU.0000000000000294","article-title":"Variation in accrual and race\/ethnicity reporting in urological and nonurological related cancer trials","volume":"202","author":"Paul","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0012","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0091-7435(86)90024-1","article-title":"Efficacy and effectiveness trials (and other phases of research) in the development of health promotion programs","volume":"15","author":"Flay","year":"1986","journal-title":"Prev Med"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0013","doi-asserted-by":"crossref","first-page":"675","DOI":"10.7326\/0003-4819-125-8-199610150-00008","article-title":"The medicalization of race: scientific legitimization of a flawed social construct","volume":"125","author":"Witzig","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0014","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/10810730.2011.604388","article-title":"Health literacy explains racial disparities in diabetes medication adherence","volume":"16","author":"Osborn","year":"2011","journal-title":"J Health Commun"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0015","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMms2029562","article-title":"Race and genetic ancestry in medicine \u2014 a time for reckoning with racism","volume":"384","author":"Borrell","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0016","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/cncr.32562","article-title":"The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65 years","volume":"126","author":"Fletcher","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0017","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev.publhealth.24.100901.140927","article-title":"Classification of race and ethnicity: implications for public health","volume":"24","author":"Mays","year":"2003","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0018","first-page":"5","article-title":"Practice setting and physician influences on judgments of colon cancer treatment by community physicians","volume":"31","author":"McFall","year":"1996","journal-title":"Health Serv Res"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0019","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00005650-199402000-00002","article-title":"Physician and practice characteristics associated with judgments about breast cancer treatment","volume":"32","author":"McFall","year":"1994","journal-title":"Med Care"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0020","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s10900-013-9681-1","article-title":"Traveling towards disease: transportation barriers to health care access","volume":"38","author":"Syed","year":"2013","journal-title":"J Community Health"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0021","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/1740774520956969","article-title":"Use of electronic recruitment methods in a clinical trial of adults with gout","volume":"18","author":"Miller","year":"2021","journal-title":"Clin Trials"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0022","first-page":"327","article-title":"Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer","volume":"23","author":"Hamel","year":"2016","journal-title":"Cancer Control J Moffitt Cancer Cent"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0023","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0024","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0025","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/1055-9965.EPI-19-1616","article-title":"Diversity of enrollment in prostate cancer clinical trials: current status and future directions","volume":"29","author":"Rencsok","year":"2020","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0026","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13187-017-1261-0","article-title":"Training needs of clinical and research professionals to optimize minority recruitment and retention in cancer clinical trials","volume":"34","author":"Niranjan","year":"2019","journal-title":"J Cancer Educ"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0027","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1353\/hpu.0.0323","article-title":"More than Tuskegee: understanding mistrust about research participation","volume":"21","author":"Scharff","year":"2010","journal-title":"J Health Care Poor Underserved"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0028","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0029","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.23986","article-title":"Sex and racial differences in bladder cancer presentation and mortality in the US: bladder CA presentation and mortality","volume":"115","author":"Scosyrev","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2021.11.015_bib0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cncr.28416","article-title":"Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation","volume":"120","author":"Cohn","year":"2014","journal-title":"Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921005147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921005147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:23:39Z","timestamp":1761042219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921005147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1078143921005147"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.11.015","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}